Boehringer Ingelheim’s Stiolto Respimat gets FDA approval

RIDGEFIELD, Conn. — The Food and Drug Administration has approved Boehringer Ingelheim's Stiolto Respimat (tiotropium bromide and olodaterol), a once-daily inhaler meant to treat obstructed airflow in patients, the company announced Tuesday. 

 

According to Danny McBryan, MD, Boehringer Ingelheim’s VP, clinical development and medical affairs, as a maintenance treatment initiated around the time of diagnosis, Stiolto Respimat has the potential to improve airflow quickly. 

 

“Patients may appreciate the benefits of a maintenance medication that improves lung function within five minutes, lasts all day and reduces the use of rescue inhalers,” McBryan said, adding that Stiolto Respimat had “proven to be more effective than either SPIRIVA or olodaterol alone, with a comparable safety profile.”